<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01715051</url>
  </required_header>
  <id_info>
    <org_study_id>TW-116541</org_study_id>
    <nct_id>NCT01715051</nct_id>
  </id_info>
  <brief_title>D-Serine for Cocaine Dependence Pilot</brief_title>
  <acronym>STED-CD</acronym>
  <official_title>A Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of D-Serine for Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theresa Winhusen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to collect pilot data on the efficacy of D-serine,&#xD;
      relative to placebo, as a cocaine dependence treatment. Secondary objectives include&#xD;
      evaluating D-serine, relative to placebo, on: 1. safety in treating cocaine-dependent adults&#xD;
      and 2. tolerability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN. This is a 12 week, 2 group randomized controlled trial that will be completed&#xD;
      in an outpatient setting. Eligible participants will be randomized to D-serine or matching&#xD;
      placebo and will be scheduled to attend three research visits per week throughout the active&#xD;
      treatment phase which begins with randomization and ends on day 7 of study week 12. A single&#xD;
      visit will be scheduled in week 13 to complete retrospective data for week 12. Participants&#xD;
      will receive D-serine or placebo throughout the 12-week active treatment phase. Randomization&#xD;
      will be in a 1:1 ratio, stratified by cocaine use frequency (&lt;10 days or ≥ 10 days in the 28&#xD;
      days prior to consent).&#xD;
&#xD;
      STUDY POPULATION. Approximately 80 participants recruited from a single site will be&#xD;
      randomized. The study population will include adults who meet Diagnostic and Statistical&#xD;
      Manual-IV-Text Revision (DSM-IV-TR) criteria for cocaine dependence who have used cocaine in&#xD;
      the 30 days prior to consent and who provide at least one benzoylecgonine (BE) positive urine&#xD;
      during screening/baseline.&#xD;
&#xD;
      TREATMENTS. Study participants will be randomly assigned to receive either D-serine (target&#xD;
      ~60 mg/kg per day) or matching placebo. All participants will receive once weekly&#xD;
      manual-guided cognitive behavioral therapy during the 12 week treatment period. Medication&#xD;
      adherence will be assessed with the Medication Events Monitoring System (MEMS).&#xD;
&#xD;
      EFFICACY ASSESSMENTS. The primary outcome measure will be cocaine abstinence for three or&#xD;
      more consecutive weeks, with abstinence during a week defined as self-report of no cocaine&#xD;
      use during the week as well as negative urine BE (BE&lt;300 ng/mL) results during the week with&#xD;
      at least two urine samples provided. Key secondary efficacy measures include the proportion&#xD;
      of urine BE negative results obtained and cocaine abstinence during study weeks 11 and 12 as&#xD;
      measured by self-report and urine BE. Other efficacy measures include drug attention bias,&#xD;
      cocaine craving, drug compulsivity, cocaine withdrawal symptoms, and treatment retention.&#xD;
&#xD;
      SAFETY ASSESSMENTS. Safety measures include urinalysis, adverse events (AEs), vitals,&#xD;
      electrocardiogram (ECG), and laboratory tests. Tolerability will be assessed by the&#xD;
      proportion of participants needing a dose reduction and being discontinued from study&#xD;
      medication.&#xD;
&#xD;
      ANALYSIS. Each outcome variable will be analyzed using appropriate statistical methods for&#xD;
      the intention-to-treat (ITT) population and the evaluable population. All participants who&#xD;
      have taken at least one study medication dose will be included in the safety analysis. Data&#xD;
      will be summarized by treatment group. Summary statistics will include the mean, sample size,&#xD;
      standard deviation, median, minimum and maximum values for continuous variables, and&#xD;
      frequencies and percentages for categorical variables.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding was not received&#xD;
  </why_stopped>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with cocaine abstinence for three or more consecutive weeks as assessed by self-report and urine BE</measure>
    <time_frame>Week 13 visit</time_frame>
    <description>The Timeline Follow-back (TLFB) procedure will be used to assess the participants' self-reported use of substances for each day of the study. Urine samples will be collected at each study visit using temperature monitoring and the validity of urine samples will be checked with the use of a commercially available adulterant test. The urine samples will be sent to a laboratory for analysis.&#xD;
The self-report and urine BE results will be combined to score each participant as cocaine abstinent or non-abstinent for each study week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of cocaine-negative Urine Drug Screens (UDS) during the treatment phase</measure>
    <time_frame>Week 13 visit</time_frame>
    <description>The proportion of cocaine-negative UDS results is calculated by the number of results negative for cocaine (BE&lt;300 ng/mL) divided by the total number of UDS results obtained for the participant during the 12 week treatment phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving cocaine abstinence during study weeks 11 and 12</measure>
    <time_frame>Week 11 and Week 12</time_frame>
    <description>To be scored as abstinent for the last two weeks of treatment, a participant must provide: 1. 14 days of self-reported use for weeks 11 and 12 with no self-reported cocaine use and 2. provide at least 2 urine samples per week for study weeks 11 and 12 with all urine results negative for BE (BE&lt;300 ng/mL). Any participant failing to meet these criteria will be scored as not abstinent. At a group level, this outcome translates into the proportion of participants in each treatment arm who are cocaine abstinent during the last two weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with nephrotoxic effects as measured by urinalysis</measure>
    <time_frame>Study week 13</time_frame>
    <description>Because this is the first outpatient study of D-serine being conducted for cocaine dependence and because cocaine can be nephrotoxic, possible nephrotoxic effects will be monitored carefully by completing microscopic urinalysis on a weekly basis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in liver function at 6 weeks</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Quantitative analysis of participant blood samples will be performed to measure liver function. Liver function will be determined by analysis of the following:creatinine, alanine aminotransferase (ALT/SGPT), aspartate aminotransferase (AST/SGOT), gamma glutamyltranspeptidase (GGT), and blood urea nitrogen (BUN).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in liver function at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Quantitative analysis of participant blood samples will be performed to measure liver function. Liver function will be determined by analysis of the following:creatinine, alanine aminotransferase (ALT/SGPT), aspartate aminotransferase (AST/SGOT), gamma glutamyltranspeptidase (GGT), and blood urea nitrogen (BUN).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>D-serine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to D-serine will receive 500 mg tablets of D-serine based on the participant's weight in addition to weekly cognitive behavioral therapy (CBT). The number of capsules prescribed will be based on the target ~60 mg/kg per day dose. In practice, the mg/kg daily dose will range between approximately 55 mg/kg and 65 mg/kg. Dosing will be bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The number of placebo capsules prescribed to a study participant per day will be based on the participant's weight and will be bid dosing to match the dosing of D-serine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-serine</intervention_name>
    <description>The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.</description>
    <arm_group_label>D-serine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy</intervention_name>
    <description>CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).</description>
    <arm_group_label>D-serine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. be 18 years of age or older&#xD;
&#xD;
          2. be able to understand the study, and having understood, provide written informed&#xD;
             consent in English&#xD;
&#xD;
          3. meet DSM-IV-TR diagnostic criteria for current (within the last 12 months) dependence&#xD;
             for cocaine,&#xD;
&#xD;
          4. have at least 1 positive urine BE specimen (&gt; 300 ng/mL) during screening/baseline&#xD;
             with a minimum of 3 urine samples tested if screening/baseline is completed within 7&#xD;
             days or a minimum of 4 urine samples tested if screening/baseline is completed during&#xD;
             a period &gt;7 days and ≤ 14 days&#xD;
&#xD;
          5. have a willingness to comply with all study procedures and medication instructions&#xD;
&#xD;
          6. be seeking treatment for cocaine dependence&#xD;
&#xD;
          7. weigh &gt;101 and &lt;340 pounds&#xD;
&#xD;
          8. if female and of child bearing potential, agree to use one of the following methods of&#xD;
             birth control:&#xD;
&#xD;
               -  oral contraceptives&#xD;
&#xD;
               -  contraceptive patch&#xD;
&#xD;
               -  barrier (diaphragm or condom)&#xD;
&#xD;
               -  intrauterine contraceptive system&#xD;
&#xD;
               -  levonorgestrel implant&#xD;
&#xD;
               -  medroxyprogesterone acetate contraceptive injection&#xD;
&#xD;
               -  complete abstinence from sexual intercourse&#xD;
&#xD;
               -  hormonal vaginal contraceptive ring&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. have current dependence, defined by DSM-IV-TR criteria, on any psychoactive substance&#xD;
             other than cocaine, alcohol, nicotine, or marijuana or physiological dependence on&#xD;
             alcohol requiring medical detoxification.&#xD;
&#xD;
          2. have been enrolled in a medication assisted treatment program for opioid dependence&#xD;
             (e.g., methadone, buprenorphine) within 2 months of consent.&#xD;
&#xD;
          3. have a medical or psychiatric condition that, in the judgment of the study physician,&#xD;
             would make study participation unsafe or which would make treatment compliance&#xD;
             difficult. Medical conditions that may compromise participant safety or study conduct&#xD;
             include, but are not limited to:&#xD;
&#xD;
               -  significant renal disease or estimated Glomerular Filtration Rate (GFR) ≤ 60&#xD;
&#xD;
               -  AIDS according to the current Centers for Disease Control (CDC) criteria for AIDS&#xD;
&#xD;
               -  liver function tests greater than 3 times the upper limit of normal&#xD;
&#xD;
               -  serum creatinine outside the normal range&#xD;
&#xD;
          4. have initiated or had a dose change in psychotropic medication in the 28 days prior to&#xD;
             randomization if currently taking psychotropic medication&#xD;
&#xD;
          5. have a known or suspected hypersensitivity to D-serine&#xD;
&#xD;
          6. be pregnant or breastfeeding or plan to become pregnant&#xD;
&#xD;
          7. plan to take any of the following agents during the treatment phase:&#xD;
&#xD;
               -  nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
&#xD;
               -  angiotensin-converting enzyme (ACE) inhibitors&#xD;
&#xD;
               -  aminoglycosides&#xD;
&#xD;
               -  angiotensin receptor blockers (ARBs)&#xD;
&#xD;
               -  calcineurin inhibitors&#xD;
&#xD;
          8. be anyone who, in the judgment of the investigator, would not be expected to complete&#xD;
             the study protocol (e.g., due to relocation from the clinic area, probable&#xD;
             incarceration, etc.)&#xD;
&#xD;
          9. be a significant suicidal/homicidal risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maryhaven, Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Botreau F, Paolone G, Stewart J. d-Cycloserine facilitates extinction of a cocaine-induced conditioned place preference. Behav Brain Res. 2006 Sep 15;172(1):173-8. doi: 10.1016/j.bbr.2006.05.012. Epub 2006 Jun 12.</citation>
    <PMID>16769132</PMID>
  </reference>
  <reference>
    <citation>Paolone G, Botreau F, Stewart J. The facilitative effects of D-cycloserine on extinction of a cocaine-induced conditioned place preference can be long lasting and resistant to reinstatement. Psychopharmacology (Berl). 2009 Jan;202(1-3):403-9. doi: 10.1007/s00213-008-1280-y. Epub 2008 Aug 10.</citation>
    <PMID>18695929</PMID>
  </reference>
  <reference>
    <citation>Thanos PK, Bermeo C, Wang GJ, Volkow ND. D-cycloserine accelerates the extinction of cocaine-induced conditioned place preference in C57bL/c mice. Behav Brain Res. 2009 May 16;199(2):345-9. doi: 10.1016/j.bbr.2008.12.025. Epub 2008 Dec 30.</citation>
    <PMID>19152811</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>October 9, 2012</study_first_submitted>
  <study_first_submitted_qc>October 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2012</study_first_posted>
  <last_update_submitted>February 5, 2014</last_update_submitted>
  <last_update_submitted_qc>February 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Theresa Winhusen</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>cocaine</keyword>
  <keyword>D-serine</keyword>
  <keyword>Drug dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01715051
org study id: TW-116541
nct id: NCT01715051
lead sponsor: 
has dmc: No
The primary objective of this study is to collect pilot data on the efficacy of D-serine,
      relative to placebo, as a cocaine dependence treatment. Secondary objectives include
      evaluating D-serine, relative to placebo, on: 1. safety in treating cocaine-dependent adults
      and 2. tolerability.
STUDY DESIGN. This is a 12 week, 2 group randomized controlled trial that will be completed
      in an outpatient setting. Eligible participants will be randomized to D-serine or matching
      placebo and will be scheduled to attend three research visits per week throughout the active
      treatment phase which begins with randomization and ends on day 7 of study week 12. A single
      visit will be scheduled in week 13 to complete retrospective data for week 12. Participants
      will receive D-serine or placebo throughout the 12-week active treatment phase. Randomization
      will be in a 1:1 ratio, stratified by cocaine use frequency (<10 days or ≥ 10 days in the 28
      days prior to consent).

      STUDY POPULATION. Approximately 80 participants recruited from a single site will be
      randomized. The study population will include adults who meet Diagnostic and Statistical
      Manual-IV-Text Revision (DSM-IV-TR) criteria for cocaine dependence who have used cocaine in
      the 30 days prior to consent and who provide at least one benzoylecgonine (BE) positive urine
      during screening/baseline.

      TREATMENTS. Study participants will be randomly assigned to receive either D-serine (target
      ~60 mg/kg per day) or matching placebo. All participants will receive once weekly
      manual-guided cognitive behavioral therapy during the 12 week treatment period. Medication
      adherence will be assessed with the Medication Events Monitoring System (MEMS).

      EFFICACY ASSESSMENTS. The primary outcome measure will be cocaine abstinence for three or
      more consecutive weeks, with abstinence during a week defined as self-report of no cocaine
      use during the week as well as negative urine BE (BE<300 ng/mL) results during the week with
      at least two urine samples provided. Key secondary efficacy measures include the proportion
      of urine BE negative results obtained and cocaine abstinence during study weeks 11 and 12 as
      measured by self-report and urine BE. Other efficacy measures include drug attention bias,
      cocaine craving, drug compulsivity, cocaine withdrawal symptoms, and treatment retention.

      SAFETY ASSESSMENTS. Safety measures include urinalysis, adverse events (AEs), vitals,
      electrocardiogram (ECG), and laboratory tests. Tolerability will be assessed by the
      proportion of participants needing a dose reduction and being discontinued from study
      medication.

      ANALYSIS. Each outcome variable will be analyzed using appropriate statistical methods for
      the intention-to-treat (ITT) population and the evaluable population. All participants who
      have taken at least one study medication dose will be included in the safety analysis. Data
      will be summarized by treatment group. Summary statistics will include the mean, sample size,
      standard deviation, median, minimum and maximum values for continuous variables, and
      frequencies and percentages for categorical variables.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Triple (Participant, Care Provider, Investigator)
measure: Proportion of participants with cocaine abstinence for three or more consecutive weeks as assessed by self-report and urine BE
time frame: Week 13 visit
description: The Timeline Follow-back (TLFB) procedure will be used to assess the participants' self-reported use of substances for each day of the study. Urine samples will be collected at each study visit using temperature monitoring and the validity of urine samples will be checked with the use of a commercially available adulterant test. The urine samples will be sent to a laboratory for analysis.
The self-report and urine BE results will be combined to score each participant as cocaine abstinent or non-abstinent for each study week.
measure: Proportion of cocaine-negative Urine Drug Screens (UDS) during the treatment phase
time frame: Week 13 visit
description: The proportion of cocaine-negative UDS results is calculated by the number of results negative for cocaine (BE<300 ng/mL) divided by the total number of UDS results obtained for the participant during the 12 week treatment phase.
measure: Proportion of participants achieving cocaine abstinence during study weeks 11 and 12
time frame: Week 11 and Week 12
description: To be scored as abstinent for the last two weeks of treatment, a participant must provide: 1. 14 days of self-reported use for weeks 11 and 12 with no self-reported cocaine use and 2. provide at least 2 urine samples per week for study weeks 11 and 12 with all urine results negative for BE (BE<300 ng/mL). Any participant failing to meet these criteria will be scored as not abstinent. At a group level, this outcome translates into the proportion of participants in each treatment arm who are cocaine abstinent during the last two weeks of treatment.
measure: Number of participants with nephrotoxic effects as measured by urinalysis
time frame: Study week 13
description: Because this is the first outpatient study of D-serine being conducted for cocaine dependence and because cocaine can be nephrotoxic, possible nephrotoxic effects will be monitored carefully by completing microscopic urinalysis on a weekly basis.
measure: Change from baseline in liver function at 6 weeks
time frame: Baseline and Week 6
description: Quantitative analysis of participant blood samples will be performed to measure liver function. Liver function will be determined by analysis of the following:creatinine, alanine aminotransferase (ALT/SGPT), aspartate aminotransferase (AST/SGOT), gamma glutamyltranspeptidase (GGT), and blood urea nitrogen (BUN).
measure: Change from baseline in liver function at Week 12
time frame: Baseline and Week 12
description: Quantitative analysis of participant blood samples will be performed to measure liver function. Liver function will be determined by analysis of the following:creatinine, alanine aminotransferase (ALT/SGPT), aspartate aminotransferase (AST/SGOT), gamma glutamyltranspeptidase (GGT), and blood urea nitrogen (BUN).
arm group label: D-serine
arm group type: Active Comparator
description: Participants randomized to D-serine will receive 500 mg tablets of D-serine based on the participant's weight in addition to weekly cognitive behavioral therapy (CBT). The number of capsules prescribed will be based on the target ~60 mg/kg per day dose. In practice, the mg/kg daily dose will range between approximately 55 mg/kg and 65 mg/kg. Dosing will be bid.
arm group label: Placebo
arm group type: Placebo Comparator
description: The number of placebo capsules prescribed to a study participant per day will be based on the participant's weight and will be bid dosing to match the dosing of D-serine.
intervention type: Drug
intervention name: D-serine
description: The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.
arm group label: D-serine
intervention type: Behavioral
intervention name: Cognitive Behavioral Therapy
description: CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).
arm group label: D-serine
arm group label: Placebo
intervention type: Drug
intervention name: Placebo
description: The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
arm group label: Placebo
other name: Sugar Pill
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
facility: 
country: United States
citation: Botreau F, Paolone G, Stewart J. d-Cycloserine facilitates extinction of a cocaine-induced conditioned place preference. Behav Brain Res. 2006 Sep 15;172(1):173-8. doi: 10.1016/j.bbr.2006.05.012. Epub 2006 Jun 12.
PMID: 16769132
citation: Paolone G, Botreau F, Stewart J. The facilitative effects of D-cycloserine on extinction of a cocaine-induced conditioned place preference can be long lasting and resistant to reinstatement. Psychopharmacology (Berl). 2009 Jan;202(1-3):403-9. doi: 10.1007/s00213-008-1280-y. Epub 2008 Aug 10.
PMID: 18695929
citation: Thanos PK, Bermeo C, Wang GJ, Volkow ND. D-cycloserine accelerates the extinction of cocaine-induced conditioned place preference in C57bL/c mice. Behav Brain Res. 2009 May 16;199(2):345-9. doi: 10.1016/j.bbr.2008.12.025. Epub 2008 Dec 30.
PMID: 19152811
responsible party type: Sponsor-Investigator
investigator affiliation: University of Cincinnati
investigator full name: Theresa Winhusen
investigator title: Associate Professor
mesh term: Cocaine-Related Disorders